BRPI1014277A2 - método para melhorar o perfil de dissolução de um material biologicamente ativo - Google Patents
método para melhorar o perfil de dissolução de um material biologicamente ativoInfo
- Publication number
- BRPI1014277A2 BRPI1014277A2 BRPI1014277A BRPI1014277A BRPI1014277A2 BR PI1014277 A2 BRPI1014277 A2 BR PI1014277A2 BR PI1014277 A BRPI1014277 A BR PI1014277A BR PI1014277 A BRPI1014277 A BR PI1014277A BR PI1014277 A2 BRPI1014277 A2 BR PI1014277A2
- Authority
- BR
- Brazil
- Prior art keywords
- improving
- active material
- biologically active
- dissolution profile
- dissolution
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1682—Processes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N25/00—Biocides, pest repellants or attractants, or plant growth regulators, characterised by their forms, or by their non-active ingredients or by their methods of application, e.g. seed treatment or sequential application; Substances for reducing the noxious effect of the active ingredients to organisms other than pests
- A01N25/12—Powders or granules
- A01N25/14—Powders or granules wettable
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/421—1,3-Oxazoles, e.g. pemoline, trimethadione
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Plant Pathology (AREA)
- Environmental Sciences (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Emergency Medicine (AREA)
- Dentistry (AREA)
- Toxicology (AREA)
- Agronomy & Crop Science (AREA)
- Pest Control & Pesticides (AREA)
- Pain & Pain Management (AREA)
- Organic Chemistry (AREA)
- Rheumatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Physics & Mathematics (AREA)
- Nanotechnology (AREA)
- Optics & Photonics (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Disintegrating Or Milling (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US17230109P | 2009-04-24 | 2009-04-24 | |
| AU2009901741A AU2009901741A0 (en) | 2009-04-24 | Method for Improving the Dissolution Profile of a Biologically Active Material | |
| PCT/AU2010/000465 WO2010121321A1 (en) | 2009-04-24 | 2010-04-23 | Method for improving the dissolution profile of a biologically active material |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BRPI1014277A2 true BRPI1014277A2 (pt) | 2016-10-18 |
Family
ID=43010604
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI1014277A BRPI1014277A2 (pt) | 2009-04-24 | 2010-04-23 | método para melhorar o perfil de dissolução de um material biologicamente ativo |
Country Status (21)
| Country | Link |
|---|---|
| US (6) | US20120165323A1 (pt) |
| EP (1) | EP2421516A4 (pt) |
| JP (3) | JP5898613B2 (pt) |
| KR (3) | KR20120047207A (pt) |
| CN (3) | CN102438600A (pt) |
| AP (2) | AP2015008965A0 (pt) |
| AU (2) | AU2010239160B2 (pt) |
| BR (1) | BRPI1014277A2 (pt) |
| CA (1) | CA2759104C (pt) |
| CO (1) | CO6470804A2 (pt) |
| EA (1) | EA201171280A1 (pt) |
| IL (1) | IL215871B (pt) |
| MA (1) | MA33293B1 (pt) |
| MX (1) | MX360545B (pt) |
| MY (1) | MY163538A (pt) |
| NZ (1) | NZ595972A (pt) |
| PH (1) | PH12015501781A1 (pt) |
| SG (1) | SG175308A1 (pt) |
| UA (1) | UA110772C2 (pt) |
| WO (1) | WO2010121321A1 (pt) |
| ZA (1) | ZA201108647B (pt) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2007264418B2 (en) | 2006-06-30 | 2012-05-03 | Iceutica Pty Ltd | Methods for the preparation of biologically active compounds in nanoparticulate form |
| MX360019B (es) * | 2009-04-24 | 2018-10-15 | Iceutica Pty Ltd | Una formulación novedosa de metaxalona. |
| SG10201607849TA (en) * | 2009-04-24 | 2016-11-29 | Iceutica Pty Ltd | Production of encapsulated nanoparticles at commercial scale |
| CN102438594A (zh) | 2009-04-24 | 2012-05-02 | 伊休蒂卡有限公司 | 吲哚美辛的新剂型 |
| EA201171284A1 (ru) * | 2009-04-24 | 2012-05-30 | Айсьютика Пти Лтд. | Новая технология изготовления напроксена |
| AP3138A (en) * | 2009-04-24 | 2015-02-28 | Iceutica Pty Ltd | Production of encapsulated nanoparticles at high volume fractions |
| JP5898613B2 (ja) * | 2009-04-24 | 2016-04-06 | イシューティカ ピーティーワイ リミテッド | 生物学的活性物質の溶解プロファイルを改善するための方法 |
| US10369108B2 (en) * | 2013-03-15 | 2019-08-06 | Mylan Laboratories, Inc. | Hot melt granulation formulations of poorly water-soluble active agents |
| US20150157646A1 (en) | 2013-09-27 | 2015-06-11 | Iceutica Inc. | Abiraterone Steroid Formulation |
| CN104644556B (zh) * | 2013-11-22 | 2018-05-22 | 沈阳药科大学 | 盐酸依福地平固体粉末及其制备方法 |
| AU2015200340B2 (en) * | 2014-02-05 | 2019-01-24 | Upl Limited | Combinations |
| US9526734B2 (en) | 2014-06-09 | 2016-12-27 | Iceutica Pty Ltd. | Formulation of meloxicam |
| US11175268B2 (en) | 2014-06-09 | 2021-11-16 | Biometry Inc. | Mini point of care gas chromatographic test strip and method to measure analytes |
| CN106537128B (zh) | 2014-06-09 | 2021-06-18 | 生物统计股份有限公司 | 用于测量分析物的低成本测试条和方法 |
| EP3310344A1 (en) * | 2015-06-19 | 2018-04-25 | Biotie Therapies, Inc. | Controlled-release tozadenant formulations |
| ES2881435T3 (es) * | 2015-10-23 | 2021-11-29 | Basf Se | Soluciones sólidas de sustancias odorantes y aromatizantes con polímeros de vinilactama |
| CN105385739B (zh) * | 2015-12-09 | 2017-09-29 | 梁尚文 | -种从金边蚂蟥中制取蛋白肽的方法 |
| CN114859028A (zh) | 2016-07-19 | 2022-08-05 | 生物统计股份有限公司 | 使用批量可校准测试条测量分析物的方法和系统 |
| CN107853670A (zh) * | 2017-10-30 | 2018-03-30 | 潍坊友容实业有限公司 | 一种盐地碱蓬生物盐提取方法 |
| CN108379238B (zh) * | 2018-01-17 | 2020-07-14 | 南昌大学 | 一种储存物理稳定性好的环孢素固体脂质纳米粒及其制备方法 |
| KR102843054B1 (ko) | 2018-05-11 | 2025-08-05 | 난징 델로바 바이오테크 컴퍼니 리미티드 | 멜록시캄 조성물, 제제 및 이의 제조 방법 및 응용 |
| AU2019332696A1 (en) * | 2018-08-31 | 2021-03-18 | Kemin Industries, Inc. | Technology for water dispersible phospholipids and lysophospholipids |
| JP2022504250A (ja) * | 2018-10-05 | 2022-01-13 | アンパサンド バイオファーマシューティカルズ インコーポレイテッド | ケトンの経皮投与のための製剤および方法 |
| US11197830B2 (en) * | 2019-02-27 | 2021-12-14 | Aft Pharmaceuticals Limited | Pharmaceutical composition containing acetaminophen and ibuprofen |
| CN113133970A (zh) * | 2020-01-17 | 2021-07-20 | 美国琛蓝营养制品股份有限公司 | 一种姜黄素复合物及其制备方法和检测方法 |
| US20230173073A1 (en) * | 2020-06-25 | 2023-06-08 | Omya International Ag | Co-ground active(s) comprising product comprising surface-reacted calcium carbonate |
| TR202017034A2 (tr) * | 2020-10-26 | 2021-09-21 | Hacettepe Ueniversitesi Rektoerluek | Kuru öğütme yöntemi̇ i̇le hazirlanan ve çözünme hizi arttirilmiş selekoksi̇b i̇çeren farmasöti̇k kompozi̇syonlar |
| CN114306253B (zh) * | 2021-11-16 | 2023-08-22 | 扬子江药业集团广州海瑞药业有限公司 | 格列美脲片剂及其制备方法 |
| JP7745851B2 (ja) * | 2021-12-24 | 2025-09-30 | 日本乳化剤株式会社 | 精製イオン液体の製造方法、セルロース溶解液および再生セルロース繊維の製造方法、ならびに繊維組成物および有機繊維コード |
| CN113996161B (zh) * | 2021-12-30 | 2022-04-19 | 河北鑫鹏新材料科技有限公司 | 一种硫转移剂及其制备方法和应用 |
| CN114732009B (zh) * | 2022-06-13 | 2022-08-23 | 山东百农思达生物科技有限公司 | 一种含有吡唑醚菌酯和烯酰吗啉的水分散粒剂的制备方法 |
| CN116196273B (zh) * | 2023-03-31 | 2025-04-29 | 江苏慧聚药业股份有限公司 | 一种美洛昔康注射液及其制备方法 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2642486B2 (ja) * | 1989-08-04 | 1997-08-20 | 田辺製薬株式会社 | 難溶性薬物の超微粒子化法 |
| AU660852B2 (en) * | 1992-11-25 | 1995-07-06 | Elan Pharma International Limited | Method of grinding pharmaceutical substances |
| JP4117811B2 (ja) * | 1997-04-22 | 2008-07-16 | 日本化薬株式会社 | フルタミド製剤及びその製法 |
| SA99191255B1 (ar) * | 1998-11-30 | 2006-11-25 | جي دي سيرل اند كو | مركبات سيليكوكسيب celecoxib |
| JP4969761B2 (ja) * | 2000-08-31 | 2012-07-04 | オバン・エナジー・リミテッド | 所望粒度を持つ固体基材の小粒子および第一材料の小粒状物を含む相乗作用性混合物を製造する方法 |
| JP2004099442A (ja) * | 2002-09-04 | 2004-04-02 | Nisshin Pharma Inc | 難溶性薬物含有製剤およびその製造方法 |
| EP1830824B1 (en) * | 2004-12-31 | 2016-01-13 | Iceutica Pty Ltd. | Nanoparticle composition and methods for synthesis thereof |
| DK1973527T3 (da) * | 2005-12-15 | 2010-02-01 | Acusphere Inc | Fremgangsmåder til fremstilling af partikelbaserede farmaceutiske formulationer til parenteral indgivelse |
| CA2631493A1 (en) * | 2005-12-15 | 2007-06-21 | Acusphere, Inc. | Processes for making particle-based pharmaceutical formulations for pulmonary or nasal administration |
| AU2007264418B2 (en) * | 2006-06-30 | 2012-05-03 | Iceutica Pty Ltd | Methods for the preparation of biologically active compounds in nanoparticulate form |
| NZ705763A (en) * | 2006-06-30 | 2016-10-28 | Iceutica Pty Ltd | Methods for the preparation of biologically active compounds in nanoparticulate form |
| JP5898613B2 (ja) * | 2009-04-24 | 2016-04-06 | イシューティカ ピーティーワイ リミテッド | 生物学的活性物質の溶解プロファイルを改善するための方法 |
| CN102438594A (zh) * | 2009-04-24 | 2012-05-02 | 伊休蒂卡有限公司 | 吲哚美辛的新剂型 |
| KR101580656B1 (ko) * | 2009-04-24 | 2015-12-30 | 아이슈티카 피티와이 리미티드 | 디클로페낙의 신규 제형 |
-
2010
- 2010-04-23 JP JP2012506283A patent/JP5898613B2/ja active Active
- 2010-04-23 EP EP10766514A patent/EP2421516A4/en not_active Withdrawn
- 2010-04-23 MX MX2011011217A patent/MX360545B/es active IP Right Grant
- 2010-04-23 MA MA34379A patent/MA33293B1/fr unknown
- 2010-04-23 NZ NZ595972A patent/NZ595972A/en unknown
- 2010-04-23 EA EA201171280A patent/EA201171280A1/ru unknown
- 2010-04-23 AP AP2015008965A patent/AP2015008965A0/en unknown
- 2010-04-23 CN CN2010800180042A patent/CN102438600A/zh active Pending
- 2010-04-23 AP AP2011005994A patent/AP3629A/xx active
- 2010-04-23 WO PCT/AU2010/000465 patent/WO2010121321A1/en not_active Ceased
- 2010-04-23 AU AU2010239160A patent/AU2010239160B2/en active Active
- 2010-04-23 CN CN201410083535.XA patent/CN103830243A/zh active Pending
- 2010-04-23 UA UAA201113805A patent/UA110772C2/uk unknown
- 2010-04-23 KR KR1020117027883A patent/KR20120047207A/ko not_active Ceased
- 2010-04-23 KR KR1020157001083A patent/KR101679522B1/ko not_active Expired - Fee Related
- 2010-04-23 CA CA2759104A patent/CA2759104C/en active Active
- 2010-04-23 MY MYPI2011005117A patent/MY163538A/en unknown
- 2010-04-23 KR KR1020167021933A patent/KR101873500B1/ko not_active Expired - Fee Related
- 2010-04-23 SG SG2011077344A patent/SG175308A1/en unknown
- 2010-04-23 US US13/265,927 patent/US20120165323A1/en not_active Abandoned
- 2010-04-23 CN CN201510169316.8A patent/CN104825396A/zh active Pending
- 2010-04-23 BR BRPI1014277A patent/BRPI1014277A2/pt not_active Application Discontinuation
-
2011
- 2011-10-23 IL IL215871A patent/IL215871B/en active IP Right Grant
- 2011-11-23 CO CO11160573A patent/CO6470804A2/es not_active Application Discontinuation
- 2011-11-24 ZA ZA2011/08647A patent/ZA201108647B/en unknown
-
2013
- 2013-06-24 US US13/925,325 patent/US20130277468A1/en not_active Abandoned
-
2015
- 2015-04-22 JP JP2015087235A patent/JP2015199736A/ja active Pending
- 2015-08-12 PH PH12015501781A patent/PH12015501781A1/en unknown
- 2015-10-14 AU AU2015243003A patent/AU2015243003A1/en not_active Abandoned
-
2017
- 2017-06-05 JP JP2017110518A patent/JP6619386B2/ja active Active
-
2018
- 2018-01-19 US US15/875,794 patent/US20180169018A1/en not_active Abandoned
-
2019
- 2019-12-17 US US16/718,105 patent/US20200375903A1/en not_active Abandoned
-
2021
- 2021-09-07 US US17/468,541 patent/US20210401753A1/en not_active Abandoned
-
2024
- 2024-10-28 US US18/929,543 patent/US20250049720A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI1014277A2 (pt) | método para melhorar o perfil de dissolução de um material biologicamente ativo | |
| BRPI1015095A2 (pt) | composição, processos para preparar uma composição e um material de poli-isocianurato , e, material de poli-isocianurato | |
| BR112013012801A2 (pt) | método para a produção de um calçado e calçado | |
| BRPI1007709A2 (pt) | "artigo e método para a preparação de um artigo" | |
| BRPI0819946A2 (pt) | Composição de matéria e método para preparar uma composição tensoativa | |
| BRPI0923748A2 (pt) | Método para a preparação de dióis | |
| BRPI1007160A2 (pt) | Método para esterilizar um material | |
| BRPI1009189A2 (pt) | método para melhorar o rendimento de um polipetídeo | |
| BR112012003365A2 (pt) | método e dispositivo para a fabricação de objetos de titânio. | |
| BR112013011856A2 (pt) | sistema de implante dental e processo para a fabricação de um sistema de implante dental | |
| BRPI1013561A8 (pt) | processo para a preparação de alogliptina | |
| BRPI0915208A2 (pt) | método e aparelho para a fabricação de material lignocelulósico torrificado | |
| BR112012002102A2 (pt) | composição farmaceutica e metodo para preparar uma composição farmaceutica | |
| BRPI0922490A2 (pt) | Método para produção de beta-santaleno | |
| ZA201106789B (en) | A method of reducing the arte of degradation of a biological material | |
| EP2427392A4 (en) | Dispenser and method | |
| DK2445543T3 (da) | Knogleerstatnings-materiale | |
| FR2948037B1 (fr) | Materiau photocatalytique | |
| EP2324768A4 (en) | TOMOGRAPHIC PROCEDURE | |
| BR112012000420A2 (pt) | método de dispensação de droga | |
| BR112012001731A2 (pt) | Processo para a preparação de 1-benzil-3-hidroximetil-1h-indazol | |
| BRPI0924621A2 (pt) | método para calibração de superfícies de material de pedra | |
| BRPI0914792A2 (pt) | processo para a preparação de polióis | |
| BRPI1010841A2 (pt) | método para a fabricação de fluoroalquilnitrilas | |
| BRPI1008557A2 (pt) | processo para a preparação de 5-/6-nitrofluoresceína |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] |
Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI |
|
| B06T | Formal requirements before examination [chapter 6.20 patent gazette] | ||
| B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
| B09B | Patent application refused [chapter 9.2 patent gazette] | ||
| B12B | Appeal against refusal [chapter 12.2 patent gazette] | ||
| B350 | Update of information on the portal [chapter 15.35 patent gazette] |